NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market on Thursday a 33 percent increase in its fourth quarter revenues that included a 47 percent spike in consumables revenues.

For the three months ended Dec. 31, 2013 the firm recorded $20.9 million in total revenues, up from $15.7 million in Q4 2012. On average, analysts expected revenues of $20.7 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.